

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

BMJ Open

Study protocol for a randomised, placebo-controlled, singleblind phase II study of the efficacy of morphine for dyspnoea in patients with interstitial lung disease (JORTC-PAL 15)

	8
Journal:	BMJ Open
Manuscript ID	bmjopen-2020-043156
Article Type:	Protocol
Date Submitted by the Author:	16-Aug-2020
Complete List of Authors:	Matsuda, Yoshinobu; National Hospital Organisation Kinki Chuo Chest Medical Center Department of Psychosomatic Internal Medicine Morita, Tatsuya; Seirei Mikatahara Hospital, Palliative and Supportive Care Oyamada, Shunsuke; Japanese Organisation for Research and Treatment of Cancer, Biostatictics Ariyoshi, Keisuke; Institute of Medical Science, The University of Tokyo, Palliative Medicine Yamaguchi, Takuhiro; Division of Biostatistics, Iwase, Satoru; Institute of Medical Science, The University of Tokyo,, Department of Palliative Medicine
Keywords:	Interstitial lung disease < THORACIC MEDICINE, PALLIATIVE CARE, Clinical trials < THERAPEUTICS

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

review only

Study protocol for a randomised, placebo-controlled, single-blind phase II study of the efficacy of morphine for dyspnoea in patients with interstitial lung disease (JORTC-

PAL 15)

Yoshinobu Matsuda,¹ Tatsuya Morita,² Shunsuke Oyamada,³ Keisuke Ariyoshi,⁴

Takuhiro Yamaguchi,⁵ Satoru Iwase⁶

¹Department of Psychosomatic Internal Medicine, National Hospital Organization

Kinki-Chuo Chest Medical Center, Sakai

²Palliative and Supportive Care Division, Seirei Mikatahara General Hospital,

Hamamatsu

³Department of Biostatistics and ⁴Department of Data Management, JORTC Data

Center, Tokyo

⁵Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai

⁶Department of Palliative Care, National Center for Geriatrics and Gerontology, Obu,

Japan

Correspondence to

Yoshinobu Matsuda

Department of Psychosomatic Internal Medicine, National Hospital Organization Kinki-

Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka, Japan

Phone: +81-72-252-3021

Fax: +81-72-251-1372

Email: matsuda.yoshinobu.tx@mail.hosp.go.jp

Word count: 2199

ABSTRACT

Introduction Dyspnoea is common in patients with interstitial lung disease (ILD) and often refractory to conventional treatment. Little is known about the efficacy of systemic morphine for dyspnoea in patients with ILD. The aim of this study is to estimate the efficacy of a single subcutaneous morphine injection for dyspnoea in patients with ILD.

Methods and analysis We will conduct a multicentre, prospective, randomised, placebo-controlled, single-blinded phase II study of a single subcutaneous morphine injection for dyspnoea in patients with ILD. Eligible subjects are ILD inpatients with dyspnoea at rest refractory to conventional treatment. The morphine dose will be 2 mg. The primary endpoint is to compare changes in dyspnoea intensity from baseline to 60 minutes after treatment, measured using an 11-point numerical rating scale, between the morphine and placebo groups.

Ethics and dissemination Ethical approval has been obtained. The results of this study will be submitted for publication in an international peer-reviewed journal and the findings will be presented at international scientific conferences.

Trial registration number jRCTs051190030; Pre-results.

Protocol version 1.21, 24 July 2019

Strengths and limitations of this study

- This is one of the few studies estimating the efficacy of systemic morphine for dyspnoea in patients with ILD.
- This study has a rigorous design including randomisation, a placebo control group, and blinding of participants.
- ► This is a single-blinded study.
- ► The observation period is short, i.e., the assessment of efficacy is within 60 minutes

after treatment and assessment of adverse events is within 24 hours after treatment.



INTRODUCTION

Interstitial lung diseases (ILDs) are a heterogeneous group of lung diseases that affect the pulmonary interstitium. They include connective tissue disease-associated ILD, drug-induced ILD, occupational and environmental ILD, sarcoidosis, and idiopathic interstitial pneumonias.¹ A population-based registry study has shown that the prevalence of ILD was 80.9 per 100,000 in men and 67.2 per 100,000 in women.² ILD is often fatal or difficult to cure^{3 4}; therefore, palliative care is essential for patients with ILD. However, palliative care available for patients with ILD is not sufficient compared to that for patients with cancer.^{5 6}

Dyspnoea is the most frequent and burdensome symptom in patients with ILD,⁷ ⁸ and is associated with a decreased quality of life in ILD.⁹⁻¹⁴ Multiple empirical studies and systematic reviews have confirmed that morphine is effective for refractory dyspnoea in patients with chronic breathlessness predominantly caused by cancer and chronic obstructive pulmonary disease.¹⁵⁻¹⁸ On the other hand, studies on the efficacy and safety of morphine in patients with ILD are greatly limited. A case series of endstage idiopathic pulmonary fibrosis patients has reported that diamorphine is an effective treatment for dyspnoea.¹⁹ A few retrospective studies have also suggested that morphine is effective in treating dyspnoea in terminally ill patients with interstitial

BMJ Open

pneumonia.^{20 21} To the best of our knowledge, no published prospective study has examined the efficacy and safety of systemic morphine for dyspnoea in patients with ILD patients.²²⁻²⁴ From the Phase I study we conducted to investigate the safety of systemic morphine and determine the recommended dose of morphine to be used in further clinical trials, we reported that the recommended dose of single subcutaneous morphine for dyspnoea in patients with ILD is 2 mg.²⁵ The aim of this study is to estimate the efficacy of a single subcutaneous morphine injection for dyspnoea in ILD patients.

METHODS AND ANALYSIS

Study design

This study is a multicentre, prospective, randomised, placebo-controlled, single-blinded phase II study and will be performed to estimate the efficacy of morphine. The study design is summarized in Figure 1.

Study settings and participants

Recruiting will be performed from nine hospitals across Japan.

The inclusion criteria are as follows: hospitalized patients who 1) are 20 years or

> older; 2) are diagnosed with ILD by two respiratory physicians and one respiratory radiologist; 3) have dyspnoea at rest despite conventional treatment, with numerical rating scale (NRS) \geq 3; 4) have an expected survival of 1 month or longer; 5) are capable of communication and do not have cognitive impairments; 6) have blood oxygen saturation levels (SpO₂) \geq 90% (supplemental oxygen was allowed) and partial pressure of carbon dioxide (PaCO₂) \leq 50 Torr; 7) have a normal liver and renal function (AST \leq 100 IU/L, ALT \leq 100 IU/L, T-Bil \leq 2.0 mg/dL, and creatinine \leq 2.0 mg/dL); and 8) have an ejection fraction \geq 50% confirmed by echocardiography.

> ILDs in this study include idiopathic pulmonary fibrosis, idiopathic non-specific interstitial pneumonia (NSIP), unclassifiable idiopathic interstitial pneumonia, collagen vascular disease-related interstitial pneumonia, chronic hypersensitive pneumonia, and pneumoconiosis. Idiopathic pulmonary fibrosis is diagnosed using the official American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Society statement.²⁶ NSIP and unclassifiable idiopathic interstitial pneumonia are diagnosed using the official American Thoracic Society/European Respiratory Society statement.²⁷

The exclusion criteria are as follows: 1) patients with contraindications to morphine, 2) patients using opioids (if the patient is receiving any dose of codeine, that

 $\overline{7}$

was discontinued 12 hours prior to the study treatment), 3) patients with acute respiratory failure, pneumothorax, or asthma attack, 4) patients with dyspnoea mainly caused by an active infection or lung cancer, 5) patients using invasive or non-invasive positive pressure ventilation, 6) patients with a current or past history of drug abuse, or 7) patients who are pregnant.

Recruitment, randomisation, masking and follow-up

Recruitment

Potentially eligible patients will be screened by site investigators. If the patients comply with the inclusion criteria, they will be invited to participate in the study.

Randomisation

During enrolment and after providing a written informed consent, patients will be randomly allocated to the intervention (morphine) or control (placebo) groups in a webbased central randomisation system using minimisation methods and a computergenerated randomisation schedule with a 1:1 allocation ratio. In performing this allocation, we will minimise the following adjustment factors to avoid a large bias: (1) current dyspnoea intensity measured by the NRS ($\leq 6, \geq 7$), (2) the use of codeine (Yes, No), and (3) the study site.

Masking

Patients will be blinded to the administration of morphine or placebo. The intervention will be unblinded 60 minutes after treatment, only if patients in the placebo group do not experience relief of dyspnoea and want to receive morphine. Clinicians and medical staff will be unblinded because the process of disposing opioid in Japan is very complex. However, clinicians or medical staff who will check the self-administered sheet for current dyspnoea intensity (primary endpoint) will be blinded.

Data management, central monitoring and audit

Evaluation will be performed at five timepoints: time of enrolment, baseline, and 30 minutes, 60 minutes, and 24 hours after treatment. The timing and details of the assessments are shown in Table 1. The investigators at each study site will keep the individual records of each patient as source data, which include signed informed consent forms, medical records, laboratory data and other records or notes. All data will be collected by the JORTC data centre. The JORTC data centre will oversee the intra-study data sharing process. The clinical data entry, data management and central

BMJ Open

monitoring will be performed using the electric data capture VIEDOC 4 (PCG Solutions, Sweden). An interim analysis will not be performed. Auditing will not be done in this study.

to perteries only

Page 12 of 28

		BMJ Open		6/bmjopen-2020-043156	
				-2020-04	
				13156	
Table 1 Study procedure and	time point for evaluation			on 1	
Time point	Inclusion	Baseline	30 minutes	60 a ninutes	24 hours
Consent, randomisation	\checkmark			ły 20	
Modified MRC scale	\checkmark			21. [
ECOG PS	\checkmark			Dowr	
Medicines History				nloac	
Smoking History	1			led fr	
Weight				-om	
AST, ALT, T-Bil, Cre	\checkmark			nttp:/	
$PaCO_2$	\checkmark			/bmj	
Ejection fraction	\checkmark			open	
NRS for current dyspnoea	\checkmark	1	1	l.bmj√	
Vital signs		\checkmark		ay 2021. Downloaded from http://bmjopen.bmj.com/	
Oxygen		\checkmark	1	9 √	
RASS		\checkmark		April	
Number of vomiting		<		<u>,</u> ,	
Adverse events		<	4	2024	

ALT, alanine aminotransferase; AST, aspartate aminotransferase; Cre, creatinine; ECOG PS, European Cooperative Oncology Group Performance Status; MRC, Medical Research Council; NRS, Numerical Rating Scale; RASS, Richmon@ Agitation-Sedation Scale; T-Bil, total bilirubin. est. Protected by copyright.

Treatment

Interventions

Single subcutaneous injection of morphine 2 mg or placebo (normal saline 0.2 mL) will be conducted. Injection will be conducted by an unblinded physician. Patients in the placebo group who do not experience relief of dyspnoea and who want to receive morphine after assessment for 60 minutes after injection will be administered 2 mg of morphine. Following previous studies,^{19 28} we decided to use subcutaneous injection, not oral preparations, for practical reasons, such as the feasibility of a placebo (normal saline) in future clinical trials, and simple logistics in the study institution.

Cotreatments

Generally, change in oxygen flow rate and oxygen delivery devices will not be allowed. In addition, hypotensive drugs, diuretics, hypnotics, anxiolytics, and anti-psychotics will not be administered one hour after treatment. Codeine will be permitted until 12 hours before treatment. The use of inhaled bronchodilators and pulmonary rehabilitation will be restricted 1 hour before and after treatment.

Data collection

Blood pressure, heart rate, respiratory rate, SpO₂, and oxygen requirement will be recorded at baseline, 30 minutes, and 60 minutes after morphine administration. Furthermore, sedation (assessed by the Richmond agitation sedation scale^{29 30}), vomiting frequency (events/60 minutes), and the Common Terminology Criteria for Adverse Events (CTCAE) will be assessed at baseline and 60 minutes after drug administration. In addition, CTCAE will be recorded for 24 hours following drug

administration.

Measures

Demographics and clinical characteristics

Participants' sex, age, body weight, type of ILD, concomitant drug use (corticosteroids, immunosupressants, anti-fibrotic agents, bronchodilators, pulmonary vasodilators, anxiolytics, and codeine), the modified Medical Research Council Dyspnea scale,³¹ the European Cooperative Oncology Group Performance Status, ejection fraction by echocardiography, PaCO₂, SpO₂, oxygen flow rate, oxygen delivery devices, AST, ALT, T-Bil, creatinine, and current dyspnoea intensity at rest in the NRS will be assessed before enrolment.

Numerical Rating Scale

Current dyspnoea intensity will be assessed by an 11-point Likert-type NRS from 0 (no dyspnoea) to 10 (worst possible dyspnoea).³²

Richmond Agitation-Sedation Scale (RASS)

Agitation and sedation will be assessed by the RASS. The RASS is a validated 10- point scale that ranges from -5 (unarousable) to +4 (combative).^{29 30}

Common Terminology Criteria for Adverse Events

The worst grade of an adverse event (AE) during the preceding period will be assessed using the CTCAE V.5.0, Japanese Clinical Oncology Group (JCOG) version. Three AEs including somnolence, nausea, and delirium will be investigated because they

BMJ Open

 occur at a relatively high frequency. Other AEs may also be assessed.

Study endpoints

Primary endpoint

The primary endpoint is a comparison of changes of dyspnoea intensity at rest from baseline to 60 minutes after treatment measured using NRS between the morphine and placebo groups.

Secondary endpoints

The secondary endpoints include the following: 1) a comparison of changes in dyspnoea intensity at rest from baseline to 30 minutes after treatment measured using NRS between the morphine and placebo groups; 2) a comparison of rates of patients with NRS \geq 1 improvement of dyspnoea intensity at rest from baseline to 60 minutes after treatment between the morphine and placebo groups; 3) respiratory rate; 4) blood pressure; 5) SpO₂; 6) heart rate; 7) the number of vomiting; 8) RASS; 9) adverse events from baseline to 24 hours after treatment.

Safety

Investigators will record all AEs in electric data capture systems. All AEs are to be followed up throughout the course. All severe AEs will be reported to the Certified Review Board and investigators in all sites and discussed.

Statistical considerations

Statistical analysis

BMJ Open

Comparison of the primary endpoint of the changes in the NRS score for dyspnoea from baseline to 60 minutes after treatment between the morphine and placebo groups will be conducted using two-sided Student's t-test at a significance level of 5% according to the intention-to-treat principle. Point estimates and 95% CIs for the difference between two group means will be calculated.

Comparison of the secondary endpoint of the changes of NRS score for dyspnoea from baseline to 30 minutes after treatment between the morphine and placebo groups will be evaluated similarly to the primary endpoint. Comparison of the rates in patients who experienced an improvement in the NRS of ≥ 1 from baseline to 30 minutes or 60 minutes after treatment will be evaluated using chi-square test or Fisher's exact test. Point estimates and 95% CIs for the difference between two means will be calculated. A full statistical analysis plan (including the handling of missing values) will be written ie4 prior to the data evaluation.

Sample size calculation

The aim of this study is to estimate the efficacy of morphine for dyspnoea in patients with ILDs and gain the data to calculate the sample size for future phase III study. Therefore, we set the sample size we will be able to enroll during three-year scheduled period.

Patient and public involvement

Patients and the public will not be involved in this study.

Ethics and dissemination

Ethics

All patients will be required to provide a written informed consent. The study will be conducted in accordance with the Declaration of Helsinki and the Clinical Trials Act. The protocol was approved by the Osaka City University Certified Review Board (CRB; approved number OCU0006). This trial has been registered at the Japan Registry of Clinical Trials (jRCT) as jRCTs051190030. This study protocol adheres to SPIRIT 2013. Modifications in the study protocol will be communicated to the CRB as well as the independent data monitoring committee of JORTC.

Dissemination

The results of this study will be submitted for publication in international peer-reviewed journals and the key findings will be presented at national and international conferences. Authorship will be ascribed in accordance with the International Committee of Medical Journal Editors guidance.

DISCUSSION

This study protocol describes multicentre, prospective, randomised, placebo-controlled, single-blinded phase II study of morphine against dyspnoea in patients with ILDs. In this phase II study, we expect to obtain data to estimate the efficacy of a single subcutaneous injection of morphine for dyspnoea in patients with ILD and be able to use the data to calculate the sample size for the phase II study.

The strengths of this study are as follows: first, this is one of the few studies to assess the efficacy of morphine for dyspnoea in patients with ILDs; second, this study is randomised placebo controlled study, therefore we can compare the efficacy of morphine with placebo even though this study is phase II study.

Several issues related to the content of the trial require discussion. First, this trial is single-blinded trial. Clinicians and medical staff, except those who check the self-administer sheet, will be unblinded. If clinicians and medical staff are blinded, other unblinded clinicians or medical staff need to dispose the treatment drug, i.e., morphine or normal saline. To minimize the burden of the clinicians and medical staff in each site, we decided that the clinicians and medical staff would be unblinded. However, the primary endpoint will be assessed using a self-administration sheet and checked by blinded clinicians or medical staff. Thus, the effect of un-blinded clinicians or staff will be minimised. Second, the observation period is short in our study, i.e., assessment of efficacy is within 60 minutes after treatment and assessment of AEs is within 24 hours after treatment. This is because we assume the patients with ILD in this study to be vulnerable, and longer study periods may result in decreased feasibility; treatments other than morphine could be changed, including providing supplemental oxygen. Finally, we do not exclude patients who use codeine because many patients with ILD use codeine for cough. However, codeine will be discontinued 12 hours prior to study treatment to minimize the effect of codeine to dyspnoea.

REFERENCES

- 1 King TE, Jr. Clinical advances in the diagnosis and therapy of the interstitial lung diseases. *Am J Respir Crit Care Med* 2005;172:268-79. doi:10.1164/rccm.200503-4830E
- 2 Coultas DB HR. Epidemiology of idiopathic pulmonary fibrosis. In: III LJ, ed. Idiopathic pulmonary fibrosis, lung biology in health and disease. New York, Marcel Dekker. 2004:772.
- 3 du Bois RM. An earlier and more confident diagnosis of idiopathic pulmonary fibrosis. *Eur Respir Rev* 2012;21:141-6. doi:10.1183/09059180.00000812
- 4 Raghu G, Collard HR, Egan JJ, *et al.* An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med* 2011;183:788-824. doi:10.1164/rccm.2009-

1		
2		
3		
4		
5		04001
б	~	040GL
7	5	Lindell KO, Liang Z, Hoffman LA, et al. Palliative care and location of death in
8		decedents with idiopathic pulmonary fibrosis. <i>Chest</i> 2015;147:423-9.
9	2	doi:10.1378/chest.14-1127
10	6	Ahmadi Z, Wysham NG, Lundstrom S, et al. End-of-life care in oxygen-dependent
11		ILD compared with lung cancer: a national population-based study. <i>Thorax</i>
12		2016;71:510-6. doi:10.1136/thoraxjnl-2015-207439
13	7	Collard HR, Pantilat SZ. Dyspnea in interstitial lung disease. Curr Opin Support
14		Palliat Care 2008;2:100-4. doi:10.1097/SPC.0b013e3282ff6336
15	8	Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic
16		subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;157:199-
17		203. doi:10.1164/ajrccm.157.1.9704130
	9	Baddini Martinez JA, Martinez TY, Lovetro Galhardo FP, et al. Dyspnea scales as a
18		measure of health-related quality of life in patients with idiopathic pulmonary
19		fibrosis. Med Sci Monit 2002;8:CR405-10
20	10	Peng S, Li Z, Kang J, et al. Cross-sectional and longitudinal construct validity of the
21	10	Saint George's Respiratory Questionnaire in patients with IPF. <i>Respirology</i>
22		2008;13:871-9. doi:10.1111/j.1440-1843.2008.01359.x
23	11	Nishiyama O, Taniguchi H, Kondoh Y, <i>et al.</i> Health-related quality of life in
24	11	
25		patients with idiopathic pulmonary fibrosis. What is the main contributing factor?
26	10	<i>Respir Med</i> 2005;99:408-14. doi:10.1016/j.rmed.2004.09.005
27	12	Zimmermann CS, Carvalho CR, Silveira KR, et al. Comparison of two
28		questionnaires which measure the health-related quality of life of idiopathic
29		pulmonary fibrosis patients. <i>Braz J Med Biol Res</i> 2007;40:179-87
30	13	Martinez TY, Pereira CA, dos Santos ML <i>, et al.</i> Evaluation of the short-form 36-
31		item questionnaire to measure health-related quality of life in patients with
32		idiopathic pulmonary fibrosis. <i>Chest</i> 2000;117:1627-32
33	14	De Vries J, Kessels BL, Drent M. Quality of life of idiopathic pulmonary fibrosis
34		patients. <i>Eur Respir J</i> 2001;17:954-61
35	15	Ekstrom M, Nilsson F, Abernethy AA, et al. Effects of opioids on breathlessness and
36		exercise capacity in chronic obstructive pulmonary disease. A systematic review.
		Ann Am Thorac Soc 2015;12:1079-92. doi:10.1513/AnnalsATS.201501-034OC
37	16	Jennings AL, Davies AN, Higgins JP, et al. A systematic review of the use of opioids
38	-	in the management of dyspnoea. <i>Thorax</i> 2002;57:939-44
39	17	Abernethy AP, Currow DC, Frith P, <i>et al.</i> Randomised, double blind, placebo
40		controlled crossover trial of sustained release morphine for the management of
41		refractory dyspnoea. <i>BMJ</i> 2003;327:523-8. doi:10.1136/bmj.327.7414.523
42	18	Currow DC, McDonald C, Oaten S, <i>et al.</i> Once-daily opioids for chronic dyspnea: a
43	10	dose increment and pharmacovigilance study. J Pain Symptom Manage
44		
45	10	2011;42:388-99. doi:10.1016/j.jpainsymman.2010.11.021
46	19	Allen S, Raut S, Woollard J, et al. Low dose diamorphine reduces breathlessness
47		without causing a fall in oxygen saturation in elderly patients with end-stage
48		idiopathic pulmonary fibrosis. <i>Palliat Med</i> 2005;19:128-30.
49		doi:10.1191/0269216305pm998oa
50	20	Takeyasu M, Miyamoto A, Kato D <i>, et al.</i> Continuous Intravenous Morphine
51		Infusion for Severe Dyspnea in Terminally Ill Interstitial Pneumonia Patients.
52		Intern Med 2016;55:725-9. doi:10.2169/internalmedicine.55.5362
52	21	Matsuda Y, Maeda I, Tachibana K, et al. Low-Dose Morphine for Dyspnea in
55 54		Terminally Ill Patients with Idiopathic Interstitial Pneumonias. J Palliat Med 2017.
		doi:10.1089/jpm.2016.0432
55	22	Ryerson CJ, Collard HR, Pantilat SZ. Management of dyspnea in interstitial lung
56	—	disease. Curr Opin Support Palliat Care 2010;4:69-75.
57		doi:10.1097/SPC.0b013e3283392b51
58	23	Ryerson CJ, Donesky D, Pantilat SZ, <i>et al.</i> Dyspnea in idiopathic pulmonary
59	20	wy or our out, boncomy b, i anonat on, et al. by spinea in interpatine pullionally
60		

י ר	
2 3	
3	
4	
5	
6	
7	
8	
9	
10	
11	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
22	
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 4 35 36 37 38	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
26	
30	
37	
38	
39	
40	
41	
42	
43	
44	
45	
45 46	
46 47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
57	
59	

	fibrosis: a systematic review. <i>J Pain Symptom Manage</i> 2012;43:771-82. doi:10.1016/j.jpainsymman.2011.04.026
24	Kohberg C, Andersen CU, Bendstrup E. Opioids: an unexplored option for treatment of dyspnea in IPF. <i>Eur Clin Respir J</i> 2016;3:30629.
	doi:10.3402/ecrj.v3.30629
25	Matsuda Y, Morita T, Miyaji T <i>, et al.</i> Morphine for Refractory Dyspnea in
	Interstitial Lung Disease: A Phase I Study (JORTC-PAL 05). J Palliat Med 2018.
	doi:10.1089/jpm.2018.0272
26	Raghu G, Remy-Jardin M, Myers JL <i>, et al.</i> Diagnosis of Idiopathic Pulmonary
	Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respin
	Crit Care Med 2018;198:e44-e68. doi:10.1164/rccm.201807-1255ST
27	Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic
	Society/European Respiratory Society statement: Update of the international
	multidisciplinary classification of the idiopathic interstitial pneumonias. Am J
	Respir Crit Care Med 2013;188:733-48. doi:10.1164/rccm.201308-1483ST

- 28 Bruera E, MacEachern T, Ripamonti C, *et al.* Subcutaneous morphine for dyspnea in cancer patients. *Ann Intern Med* 1993;119:906-7
- 29 Sessler CN, Gosnell MS, Grap MJ, *et al.* The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. *Am J Respir Crit Care Med* 2002;166:1338-44. doi:10.1164/rccm.2107138
- 30 Unoki K SH, Okimura A, Takeshima C, Aoki K, Otani N, Mochizuki T, Yanagisawa Y. Japanese version of the Richmond Agitation Scale. J Jpn Soc Intensive Care Med 2010;17:73-4
- 31 Bestall JC, Paul EA, Garrod R, *et al.* Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. *Thorax* 1999;54:581-6. doi:10.1136/thx.54.7.581
- Yokomichi N, Morita T, Nitto A, et al. Validation of the Japanese Version of the Edmonton Symptom Assessment System-Revised. J Pain Symptom Manage 2015;50:718-23. doi:10.1016/j.jpainsymman.2015.05.014

Authors' Contributions

YM is lead author of the study protocol and principal investigator. YM, TM, SO, KA, TY and SI participated in the design of the study. SO and TY designed the statistical analysis plan. All authors contributed to writing and revising the manuscript critically, and all gave their final approve of the version to be published.

Funding statement

This work was supported by the following grants: 2018-2020 Grant-in-Aid for Scientific Research (Grant-in-Aid for Young Scientists B; grant number 17K15909) and Osaka Medical Research Foundation for Intractable Diseases (grant number 23-2-41). The funders had no role in the study design and will have no role in the data collection, analysis or dissemination of study results.

JICN.

Competing interests None declared.

Trial status

The enrolment started in June 2019. At the time of manuscript submission (July 2020), 17 patients have participated. We expect to complete the recruitment by March 2022.

Confidentially

Data will be retained in accordance with the Clinical Trials Act. Participants will be allocated a unique identification (ID) number at entry. The master list linking participant personal information and ID number will be maintained in a paper file or password-protected hard drive in a locked room at each institution. Data will be analysed by ID number only. Records will be retained for 5 years after study completion and then destroyed by the JORTC data centre.

Acknowledgements

This work was supported by the following grants: 2018-2020 Grant-in-Aid for Scientific Research (Grant-in-Aid for Young Scientists B; grant number 17K15909) and Research Found Osaka Medical Research Foundation for Intractable Diseases (grant number 23-2-41).

Figure Legend

Figure 1 Flow chart of the procedures in the study. Participants will be randomized (1:1 allocation ratio) into the morphine group or the placebo group. Assessment will be made at baseline, 30 minutes, 60 minutes, and 24 hours. AEs, Adverse Events; ILD, Interstitial Lung Disease; IPPV, Invasive Positive Pressure Ventilation; NPPV, Non-invasive Positive Pressure Ventilation; RASS, Richmond Agitation Sedation Scale.

or oper teries only

BMJ Open




Figure 1 Flow chart of the procedures in the study. Participants will be randomized (1:1 allocation ratio) into the morphine group or the placebo group. Assessment will be made at baseline, 30 minutes, 60 minutes, and 24 hours. AEs, Adverse Events; ILD, Interstitial Lung Disease; IPPV, Invasive Positive Pressure Ventilation; NPPV, Non-invasive Positive Pressure Ventilation; RASS, Richmond Agitation Sedation Scale.

274x383mm (300 x 300 DPI)

Page	25 of 28	BMJ Open		
1 2 3 4 5 6			STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS	
7 8	SPIRIT 2013 Check	klist: Rec	ommended items to address in a clinical trial protocol and related documents*	
9 10 11	Section/item	ltem No	Description Do	Addressed on page number
12 13 14	Administrative inf	ormatior		
15 16	Title	1	Descriptive title identifying the study design, population, interventions, and, if applicated acronym	p1
17 18 19 20 21 22 23 24	Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	р3
		2b	All items from the World Health Organization Trial Registration Data Set	Not applicable
	Protocol version	3	Date and version identifier	р3
	Funding	4	Sources and types of financial, material, and other support	p20
25 26	Roles and	5a	Names, affiliations, and roles of protocol contributors	p1, 20
27 28	responsibilities	5b	Name and contact information for the trial sponsor	Not applicable
29 30 31 32		5c	Role of study sponsor and funders, if any, in study design; collection, management, agalysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	p20
33 34 35 36 37 38 39 40 41 42		5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	p9
42 43 44 45 46			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	1

			BMJ Open <u>BMJ Open</u>	Page 26 c
1 2	Introduction			
- 3 4 5	Background and rationale	6a	Description of research question and justification for undertaking the trial, including sugmary of relevant studies (published and unpublished) examining benefits and harms for each intervent	p5-6
6 7		6b	Explanation for choice of comparators $\frac{3}{2}$	p12
8 9	Objectives	7	Specific objectives or hypotheses	p6
10 11 12 13	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	p6
14 15	Methods: Participa	nts, inte	erventions, and outcomes	
16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	p6-7
	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	p6-7
	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	p12
		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	Not applicable
		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	Not applicable
		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	p12
	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), methed of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	p13-14
40 41 42	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	p12-13
43 44 45			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	2

Page 27 of 28			BMJ Open <u>BMJ Open</u>	
1 2	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was getermined, including clinical and statistical assumptions supporting any sample size calculations	p15
3 4 5	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size $\frac{1}{3}$	p8
6 7	Methods: Assignm	ent of ir	nterventions (for controlled trials) $\overrightarrow{\mathbf{a}}$	
8 9	Allocation:		Y May 20	
10 11 12 13 14 15	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	p8
16 17 18 19	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until intervantions are assigned	р8
20 21 22 23	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	p8
23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 20	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care provine assessors, data analysts), and how	p9
		17b	If blinded, circumstances under which unblinding is permissible, and procedure for reyealing a participant's allocated intervention during the trial	p9
	Methods: Data collection, management, and analysis			
	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and additive of and a description of Reference to where data collection forms can be found, if not in the protocol	p12-13
38 39 40 41 42		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	Not applicable
43 44 45 46			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	3

			BMJ Open <u>3</u> . ල	Page 2
1 2 3 4 5 6 7	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	p8-9
	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where \vec{g} other details of the statistical analysis plan can be found, if not in the protocol	p14-15
8 9		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	Not applicable
9 10 11 12 13		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	p15
14 15	Methods: Monitorin	ng	aded a	
16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of way a DMC is not needed	p16
		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	Not applicable
	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	p14
	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process \vec{w} ill be independent from investigators and the sponsor	p10
32 33	Ethics and dissemi	nation	by gues	
34 35 36 37 38 39 40 41 42	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	p15-16
	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility creteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	p16
43 44 45 46			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	-

Page 29 of 28			BMJ Open <u>ප</u> වූ	
1 2	Consent or assent	26a	딱 Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	p15
3 4 5 6		26b	Additional consent provisions for collection and use of participant data and biological \hat{s} pecimens in ancillary studies, if applicable	Not applicable
7 8 9	Confidentiality	27	How personal information about potential and enrolled participants will be collected, spared, and maintained in order to protect confidentiality before, during, and after the trial	p9-10, 20-21
10 11 12	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	p20
13 14 15	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contracteal agreements that limit such access for investigators	Not applicable
16 17 18	Ancillary and post- trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	p12
19 20 21 22 23	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, health care professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	p16
24 25		31b	Authorship eligibility guidelines and any intended use of professional writers	p16
26 27 28		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	Not applicable
29 30	Appendices			
30 31 32 33	Informed consent materials	32	Model consent form and other related documentation given to participants and author $\frac{1}{2}$ be surrogates	Not applicable
33 34 35 36	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	Not applicable
37 38 39 40 41	Amendments to the p	protocol	that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarificati I should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Com -NoDerivs 3.0 Unported" license.	
42 43 44 45 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml 45				ł

BMJ Open

BMJ Open

Study protocol for a randomised, placebo-controlled, singleblind phase II study of the efficacy of morphine for dyspnoea in patients with interstitial lung disease (JORTC-PAL 15)

Journal:	BMJ Open
Manuscript ID	bmjopen-2020-043156.R1
Article Type:	Protocol
Date Submitted by the Author:	16-Feb-2021
Complete List of Authors:	Matsuda, Yoshinobu; National Hospital Organisation Kinki Chuo Chest Medical Center Department of Psychosomatic Internal Medicine Morita, Tatsuya; Seirei Mikatahara Hospital, Palliative and Supportive Care Oyamada, Shunsuke; Japanese Organisation for Research and Treatment of Cancer, Biostatictics Ariyoshi, Keisuke; Institute of Medical Science, The University of Tokyo, Palliative Medicine Yamaguchi, Takuhiro; Division of Biostatistics, Iwase, Satoru; Institute of Medical Science, The University of Tokyo,, Department of Palliative Medicine
Primary Subject Heading :	Respiratory medicine
Secondary Subject Heading:	Palliative care, Respiratory medicine
Keywords:	Interstitial lung disease < THORACIC MEDICINE, PALLIATIVE CARE, Clinical trials < THERAPEUTICS

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

relievon

Study protocol for a randomised, placebo-controlled, single-blind phase II study of the efficacy of morphine for dyspnoea in patients with interstitial lung disease (JORTC-

PAL 15)

Yoshinobu Matsuda,¹ Tatsuya Morita,² Shunsuke Oyamada,³ Keisuke Ariyoshi,⁴

Takuhiro Yamaguchi,⁵ Satoru Iwase⁶

¹Department of Psychosomatic Internal Medicine, National Hospital Organization

Kinki-Chuo Chest Medical Center, Sakai

²Palliative and Supportive Care Division, Seirei Mikatahara General Hospital,

Hamamatsu

³Department of Biostatistics and ⁴Department of Data Management, JORTC Data

Center, Tokyo

⁵Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai

⁶Department of Palliative Care, National Center for Geriatrics and Gerontology, Obu,

Japan

Correspondence to

Yoshinobu Matsuda

Department of Psychosomatic Internal Medicine, National Hospital Organization Kinki-

Chuo Chest Medical Center, 1180 Nagasone-cho, Kita-ku, Sakai, Osaka, Japan

Phone: +81-72-252-3021

Fax: +81-72-251-1372

Email: matsuda.yoshinobu.tx@mail.hosp.go.jp

Word count: 2480

ABSTRACT

Introduction Dyspnoea is common in patients with interstitial lung disease (ILD) and often refractory to conventional treatment. Little is known about the efficacy of systemic morphine for dyspnoea in patients with ILD. The aim of this study is to estimate the efficacy of a single subcutaneous morphine injection for dyspnoea in patients with ILD.

Methods and analysis We will conduct a multicentre, prospective, randomised, placebo-controlled, single-blinded phase II study of a single subcutaneous morphine injection for dyspnoea in patients with ILD. Inpatients with ILD who have dyspnoea at rest refractory to conventional treatment will be eligible for participation in this study. The morphine dose will be 2 mg. The primary endpoint is changes in dyspnoea intensity from baseline to 60 minutes after treatment as measured using an 11-point numerical rating scale and compared between the morphine and placebo groups.

Ethics and dissemination Ethical approval has been obtained by the Osaka City University Certified Review Board. The results of this study will be submitted for publication in an international peer-reviewed journal and the findings will be presented at international scientific conferences.

Trial registration number jRCTs051190030; Pre-results.

1 2 3 4 5 6	Protocol version 1.21, 24 July 2019
7 8 9 10 11 12 13 14 15 16 17	
17 18 19 20 21 22 23 24 25 26 27 28	
29 30 31 32 33 34 35 36 37 38	
39 40 41 42 43 44 45 46 47 48 49 50	
51 52 53 54 55 56 57 58 59 60	

Strengths and limitations of this study

- This is one of the few studies estimating the efficacy of systemic morphine for dyspnoea in patients with interstitial lung disease.
- This study has a rigorous design including randomisation, a placebo control group, and blinding of participants.
- ► This is a single-blinded study.
- ► The observation period is short, i.e., efficacy is assessed within 60 minutes after treatment and monitoring for adverse events is performed for 24 hours after

treatment.

INTRODUCTION

Interstitial lung diseases (ILDs) are a heterogeneous group of lung diseases that affect the pulmonary interstitium. They include connective tissue disease-associated ILD, drug-induced ILD, occupational and environmental ILD, sarcoidosis, and idiopathic interstitial pneumonias.¹ A population-based registry study has shown that the prevalence of ILD was 80.9 per 100,000 in men and 67.2 per 100,000 in women.² ILD is often fatal or difficult to cure^{3 4}; therefore, palliative care is essential for patients with ILD. However, palliative care available for patients with ILD is insufficient compared to that for patients with cancer.^{5 6}

Dyspnoea is the most frequent and burdensome symptom in patients with ILD,⁷ ⁸ and it is associated with a decreased quality of life.⁹⁻¹⁴ Multiple empirical studies and systematic reviews have confirmed that morphine is effective for refractory dyspnoea in patients with chronic breathlessness predominantly caused by cancer and chronic obstructive pulmonary disease.¹⁵⁻¹⁸ On the other hand, studies on the efficacy and safety of morphine in patients with ILD are limited. A case series of patients with end-stage idiopathic pulmonary fibrosis has reported that diamorphine is an effective treatment for dyspnoea.¹⁹ A few retrospective studies have also suggested that morphine is effective in treating dyspnoea in terminally ill patients with interstitial pneumonia.^{20 21} A randomised controlled trial found that oral morphine did not significantly reduce dyspnoea compared with placebo in patients with fibrotic ILD.²² To the best of our knowledge, no published prospective study other than the one mentioned above has examined the efficacy and safety of systemic morphine for dyspnoea in patients with ILD.²³⁻²⁵ From the Phase I study we conducted to investigate the safety of systemic morphine and determine the recommended dose of morphine to be used in further clinical trials, we reported that the recommended dose of single subcutaneous morphine for dyspnoea in patients with ILD is 2 mg.²⁶ The aim of this study is to estimate the efficacy of a single subcutaneous morphine injection for dyspnoea in patients with ILD.

METHODS AND ANALYSIS

Study design

This is a multicentre, prospective, randomised, placebo-controlled, single-blinded phase II study that will be performed to estimate the efficacy of morphine. The study design is summarized in Figure 1.

ien

Study settings and participants

Participants will be recruited from nine hospitals across Japan.

BMJ Open

The inclusion criteria are as follows: hospitalized patients who 1) are 20 years or older; 2) have been diagnosed with ILD by two respiratory physicians and one respiratory radiologist; 3) have dyspnoea at rest with numerical rating scale (NRS) \geq 3 despite conventional treatment; 4) have an expected survival of 1 month or longer; 5) are capable of communication and do not have cognitive impairments; 6) have blood oxygen saturation levels (SpO₂) \geq 90% (supplemental oxygen was allowed) and partial pressure of carbon dioxide (PaCO₂) \leq 50 Torr; 7) have normal liver and renal function (aspartate aminotransferase [AST] \leq 100 IU/L, alanine aminotransferase [ALT] \leq 100 IU/L, total bilirubin [T-Bil] \leq 2.0 mg/dL, and creatinine \leq 2.0 mg/dL); and 8) have an ejection fraction \geq 50% as confirmed on echocardiography.

ILDs in this study include idiopathic pulmonary fibrosis, idiopathic non-specific interstitial pneumonia (NSIP), unclassifiable idiopathic interstitial pneumonia, collagen vascular disease-related interstitial pneumonia, chronic hypersensitivity pneumonia, and pneumoconiosis. Idiopathic pulmonary fibrosis is diagnosed according to the criteria in the official American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Society statement.²⁷ NSIP and unclassifiable idiopathic interstitial pneumonia are diagnosed according to the criteria in the official American Thoracic Society/European Respiratory Society statement.²⁸ **BMJ** Open

> The exclusion criteria are as follows: 1) patients with contraindications to morphine including allergy to morphine, 2) patients using opioids (if the patient is receiving any dose of codeine, that was discontinued 12 hours prior to the study treatment), 3) patients with acute respiratory failure, pneumothorax, or asthma attack, 4) patients with dyspnoea predominantly due to an active infection or lung cancer, 5) patients using invasive or non-invasive positive pressure ventilation, 6) patients with a current or past history of drug abuse, or 7) patients who are pregnant.

> We do not exclude patients who use codeine because codeine is frequently used for cough in patients with ILD. We exclude other weak opioids such as tramadol.

Recruitment, randomisation, masking and follow-up

Recruitment

Potentially eligible patients will be screened by site investigators. Patients who fit the inclusion criteria will be invited to participate in the study.

Randomisation

During enrolment and after providing a written informed consent, patients will be randomly allocated to the intervention (morphine) or control (placebo) groups by a web-

BMJ Open

based central randomisation system using minimisation methods and a computergenerated randomisation schedule with a 1:1 allocation ratio. In performing this allocation, we will minimise the following adjustment factors to avoid a large bias: (1) current dyspnoea intensity as measured using the NRS ($\leq 6, \geq 7$), (2) codeine use (Yes, No), and (3) study site.

Masking

Patients will be blinded to the administration of morphine or placebo. The intervention will only be unblinded 60 minutes after treatment, if patients in the placebo group do not experience dyspnoea relief and wish to receive morphine. Clinicians and medical staff will be unblinded because the process of disposing opioids in Japan is very complex. However, the clinicians or medical staff who will check the self-administered questionnaire for current dyspnoea intensity (primary endpoint) will be blinded.

Data management, central monitoring and audit

Evaluation will be performed at five timepoints: enrolment; baseline; and 30 minutes, 60 minutes, and 24 hours after treatment. The timing and details of the assessments are shown in Table 1. The investigators at each study site will maintain records of each

> patient as source data, which include signed informed consent forms, medical records, laboratory data and other records or notes. All data will be collected by the JORTC data centre. The JORTC data centre will oversee the intra-study data sharing process. Clinical data entry, data management and central monitoring will be performed using the VIEDOC 4 (PCG Solutions, Sweden) electric data capture system. An interim analysis will not be performed. Auditing will not be done in this study. e per rom

Table 1 Study procedure and tin	no point for ovoluciti	BMJ Open		6/bmjopen-2020-043156 or	
Time point	Inclusion	Baseline	30 minutes	9 60 minutes	24 hours
Consent, randomisation	\checkmark			ay 2021. Downloaded from http://bmjopen.bmj.com/ on April 1	
Modified MRC scale	\checkmark			021.	
ECOG PS	\checkmark			Dow	
Medicines History				nloac	
Smoking History	1			ded f	
Weight				rom	
AST, ALT, T-Bil, Cre	1			http:/	
$PaCO_2$	\checkmark			//bmj	
Ejection fraction	\checkmark			oper	
NRS for current dyspnoea	\checkmark	1	1	i.bmj√	
Vital signs		1		.co √	
Oxygen		\checkmark	1	√ on	
RASS		\checkmark		April	
Number of vomiting		←		, e +	
Adverse events		<		2024	

ALT, alanine aminotransferase; AST, aspartate aminotransferase; Cre, creatinine; ECOG PS, European Cooperative Oncology Group Performance Status; MRC, Medical Research Council; NRS, Numerical Rating Scale; PaCO₂, arterial fartial pressure of carbon dioxide; RASS, Richmond Agitation-Sedation Scale; T-Bil, total bilirubin. est. Protected by copyright.

Treatment

Interventions

Single subcutaneous injection of morphine 2 mg or placebo (normal saline 0.2 mL) will be performed. Injection will be performed by an unblinded physician. Patients in the placebo group who do not experience dyspnoea relief and who wish to receive morphine after the assessment performed 60 minutes after injection will be administered 2 mg of morphine. Following previous studies,^{19 29} we decided to use subcutaneous injection, not oral preparations, for practical reasons, such as the feasibility of a placebo (normal saline) in future clinical trials, and simple logistics at the study site.

Cotreatments

Uniformity in oxygen flow rate and oxygen delivery device use will be maintained except in cases of unacceptable hypoxia. In addition, hypotensive drugs, diuretics, hypnotics, anxiolytics, and anti-psychotics will not be administered until one hour after treatment. Codeine use will be permitted until 12 hours before treatment. The use of inhaled bronchodilators and pulmonary rehabilitation will be restricted for 1 hour before and after treatment.

Data collection

Blood pressure, heart rate, respiratory rate, SpO₂, and oxygen requirement will be recorded at baseline and at 30 and 60 minutes after morphine administration. Furthermore, sedation (assessed using the Richmond Agitation Sedation Scale^{30 31}), vomiting frequency (events/60 minutes), and the Common Terminology Criteria for Adverse Events (CTCAE) will be assessed at baseline and 60 minutes after drug

 BMJ Open

administration. In addition, the CTCAE of all patients will be recorded for 24 hours following drug administration.

Measures

Demographics and clinical characteristics

Participants' sex, age, body weight, type of ILD, concomitant drug use (corticosteroids, immunosupressants, anti-fibrotic agents, bronchodilators, pulmonary vasodilators, anxiolytics, and codeine), the modified Medical Research Council Dyspnea scale,³² the European Cooperative Oncology Group Performance Status, ejection fraction on echocardiography, PaCO₂, SpO₂, oxygen flow rate, oxygen delivery devices, AST, ALT, T-Bil, creatinine, and current dyspnoea intensity at rest in the NRS will be erie assessed before enrolment.

Numerical Rating Scale

Current dyspnoea intensity will be assessed using an 11-point Likert-type NRS from 0 (no dyspnoea) to 10 (worst possible dyspnoea).³³

Richmond Agitation-Sedation Scale (RASS)

Agitation and sedation will be assessed using the RASS. The RASS is a validated 10point scale that ranges from -5 (unarousable) to +4 (combative). 3031

Common Terminology Criteria for Adverse Events

The worst grade of an adverse event (AE) during the preceding period will be assessed using the CTCAE V.5.0, Japanese Clinical Oncology Group version. Three AEs

including somnolence, nausea, and delirium will be investigated because they occur at a relatively high frequency. Other AEs may also be assessed.

Study endpoints

Primary endpoint

The primary endpoint is the changes in dyspnoea intensity at rest from baseline to 60 minutes after treatment as measured using the NRS and compared between the morphine and placebo groups.

Secondary endpoints

The secondary endpoints include the following: 1) changes in dyspnoea intensity at rest from baseline to 30 minutes after treatment as measured using the NRS between the morphine and placebo groups; 2) percentage of patients with NRS \geq 1 improvement in dyspnoea intensity at rest from baseline to 60 minutes after treatment and compared between the morphine and placebo groups; 3) respiratory rate; 4) blood pressure; 5) SpO₂; 6) heart rate; 7) the frequency of vomiting; 8) RASS; 9) adverse events from baseline to 24 hours after treatment.

Safety

Investigators will record all AEs in electronic data capture systems. All AEs will be followed up throughout the course. All severe AEs will be reported to the Certified Review Board and investigators at all sites and discussed.

Statistical considerations

Statistical analysis

Comparison of the primary endpoint of changes in NRS score for dyspnoea from baseline to 60 minutes after treatment between the morphine and placebo groups will be conducted using the two-sided Student's t-test or Wilcoxon rank-sum test, as appropriate, at a significance level of 5% according to the intention-to-treat principle. Point estimates and 95% confidence intervals (Cis) for the difference between two group means will be calculated.

Comparison of the secondary endpoint of changes in NRS score for dyspnoea from baseline to 30 minutes after treatment between the morphine and placebo groups will be evaluated similarly to the primary endpoint. Comparison of the rates of patients who experienced improvement in the NRS of ≥ 1 from baseline to 30 minutes or 60 minutes after treatment will be evaluated using the chi-square test or Fisher's exact test. Point estimates and 95% CIs for the difference between two means will be calculated. A full statistical analysis plan (including the handling of missing values) will be written prior to the data evaluation. We will report adverse events separately for patients who receive placebo alone and for those who receive placebo followed by morphine.

Sample size calculation

The aim of this study is to estimate the efficacy of morphine for dyspnoea in patients with ILDs and gain the data to calculate the sample size for future phase III study. Therefore, we set the sample size as all patients we will be able to enrol during the three-year scheduled period. We plan to recruit 50 patients (25 patients in each group).

Patient and public involvement

Patients and the public will not be involved in this study. However, the Certified Review Board included a representative of a patient group as a member to assess our protocol.

Ethics and dissemination

Ethics

All patients will be required to provide a written informed consent. The study will be conducted in accordance with the Declaration of Helsinki and the Clinical Trials Act. The protocol was approved by the Osaka City University Certified Review Board (CRB; approved number OCU0006). This trial has been registered at the Japan Registry of Clinical Trials (jRCT) as jRCTs051190030. This study protocol adheres to SPIRIT 2013. Modifications in the study protocol will be communicated to the CRB as well as the independent data monitoring committee of the JORTC.

Dissemination

The results of this study will be submitted for publication in international peer-reviewed journals and the key findings will be presented at national and international conferences. Authorship will be ascribed in accordance with the International Committee of Medical Journal Editors guidelines.

DISCUSSION

This study protocol describes multicentre, prospective, randomised, placebo-controlled, single-blinded phase II study of morphine against dyspnoea in patients with ILDs. In this phase II study, we expect to obtain data to estimate the efficacy of a single

BMJ Open

subcutaneous injection of morphine for dyspnoea in patients with ILD and be able to use the data to calculate the sample size for the phase III study.

Recently, Kronborg-White et al. found in a randomised controlled trial that oral morphine did not significantly reduce dyspnoea compared with placebo in patients with fibrotic ILD.¹⁷ Despite similarities between their trial and our study, there are some differences. First, their trial included outpatients with Medical Research Council scores of \geq 3, while our study included inpatients with dyspnoea at rest in NRS \geq 3. Therefore the patients in our study would be at a more terminal stage of their illness than the patients in their study. Second, the primary endpoint of their study was dyspnoea during the past week, whereas we plan to assess current dyspnoea at rest. Furthermore, trial conducted by Kronborg-White et al. was small, and theirs was a single-centre study. Therefore the efficacy of morphine for dyspnoea in patients with ILD should be evaluated in other studies such as ours.

The strengths of this study are as follows: first, this is one of the few studies to assess the efficacy of morphine for dyspnoea in patients with ILD. Second, this study is a randomised placebo-controlled study; therefore, we can compare the efficacy of morphine with placebo even though this is phase II study.

Several issues related to the content of the trial require discussion. First, this is a single-blinded trial. Clinicians and medical staff, except those who check the selfadministered sheet, will be unblinded. If clinicians and medical staff are blinded, other unblinded clinicians or medical staff will be needed to dispose of the treatment drug, i.e., morphine or normal saline. To minimize the burden on the clinicians and medical staff at each site, we decided that the clinicians and medical staff would be unblinded. However, the primary endpoint will be assessed using a self-administered sheet and

checked by blinded clinicians or medical staff. Thus, the effect of un-blinded clinicians or staff will be minimised. Second, the observation period in our study is short, i.e., efficacy is assessed within 60 minutes after treatment and monitoring for AEs is performed for 24 hours after treatment. This is because we assume the patients with ILD in this study to be vulnerable, and longer study periods may result in decreased feasibility; treatments other than morphine could be changed and supplemental oxygen could be provided. Finally, we will not exclude patients who use codeine because many patients with ILD use codeine for cough. However, codeine will be discontinued for 12 hours prior to the study intervention to minimize its effect on dyspnoea.

REFERENCES

- 1King TE, Jr. Clinical advances in the diagnosis and therapy of the interstitial lung
diseases. Am J Respir Crit Care Med 2005;172:268-79. doi:10.1164/rccm.200503-
4830E
- 2 Coultas DB HR. Epidemiology of idiopathic pulmonary fibrosis. In: III LJ, ed. Idiopathic pulmonary fibrosis, lung biology in health and disease. New York, Marcel Dekker. 2004:772.
- 3 du Bois RM. An earlier and more confident diagnosis of idiopathic pulmonary fibrosis. *Eur Respir Rev* 2012;21:141-6. doi:10.1183/09059180.00000812
- 4 Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824. doi:10.1164/rccm.2009-040GL
- Lindell KO, Liang Z, Hoffman LA, *et al.* Palliative care and location of death in decedents with idiopathic pulmonary fibrosis. *Chest* 2015;147:423-9. doi:10.1378/chest.14-1127
- 6 Ahmadi Z, Wysham NG, Lundstrom S, *et al.* End-of-life care in oxygen-dependent ILD compared with lung cancer: a national population-based study. *Thorax* 2016;71:510-6. doi:10.1136/thoraxjnl-2015-207439
- 7 Collard HR, Pantilat SZ. Dyspnea in interstitial lung disease. *Curr Opin Support Palliat Care* 2008;2:100-4. doi:10.1097/SPC.0b013e3282ff6336
- 8 Bjoraker JA, Ryu JH, Edwin MK, *et al.* Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 1998;157:199-203. doi:10.1164/ajrccm.157.1.9704130
- 9 Baddini Martinez JA, Martinez TY, Lovetro Galhardo FP, *et al.* Dyspnea scales as a measure of health-related quality of life in patients with idiopathic pulmonary fibrosis. *Med Sci Monit* 2002;8:CR405-10
- 10 Peng S, Li Z, Kang J, *et al.* Cross-sectional and longitudinal construct validity of the Saint George's Respiratory Questionnaire in patients with IPF. *Respirology* 2008;13:871-9. doi:10.1111/j.1440-1843.2008.01359.x

BMJ Open

1		
2		
3		
4		
5	11	Nishiyama O, Taniguchi H, Kondoh Y, et al. Health-related quality of life in
6	11	patients with idiopathic pulmonary fibrosis. What is the main contributing factor?
7		Respir Med 2005;99:408-14. doi:10.1016/j.rmed.2004.09.005
8	12	Zimmermann CS, Carvalho CR, Silveira KR, <i>et al.</i> Comparison of two
9		questionnaires which measure the health-related quality of life of idiopathic
10		pulmonary fibrosis patients. <i>Braz J Med Biol Res</i> 2007;40:179-87
11	13	Martinez TY, Pereira CA, dos Santos ML, <i>et al.</i> Evaluation of the short-form 36-
12	10	item questionnaire to measure health-related quality of life in patients with
13		idiopathic pulmonary fibrosis. <i>Chest</i> 2000;117:1627-32
14	14	De Vries J, Kessels BL, Drent M. Quality of life of idiopathic pulmonary fibrosis
15		patients. <i>Eur Respir J</i> 2001;17:954-61
16	15	Ekstrom M, Nilsson F, Abernethy AA, <i>et al.</i> Effects of opioids on breathlessness and
17		exercise capacity in chronic obstructive pulmonary disease. A systematic review.
18		Ann Am Thorac Soc 2015;12:1079-92. doi:10.1513/AnnalsATS.201501-034OC
19	16	Jennings AL, Davies AN, Higgins JP, et al. A systematic review of the use of opioids
20		in the management of dyspnoea. <i>Thorax</i> 2002;57:939-44
21	17	Abernethy AP, Currow DC, Frith P, et al. Randomised, double blind, placebo
22		controlled crossover trial of sustained release morphine for the management of
23 24		refractory dyspnoea. <i>BMJ</i> 2003;327:523-8. doi:10.1136/bmj.327.7414.523
24 25	18	Currow DC, McDonald C, Oaten S, et al. Once-daily opioids for chronic dyspnea: a
26		dose increment and pharmacovigilance study. J Pain Symptom Manage
20 27		2011;42:388-99. doi:10.1016/j.jpainsymman.2010.11.021
28	19	Allen S, Raut S, Woollard J <i>, et al.</i> Low dose diamorphine reduces breathlessness
28		without causing a fall in oxygen saturation in elderly patients with end-stage
30		idiopathic pulmonary fibrosis. <i>Palliat Med</i> 2005;19:128-30.
31		doi:10.1191/0269216305pm998oa
32	20	Takeyasu M, Miyamoto A, Kato D <i>, et al.</i> Continuous Intravenous Morphine
33		Infusion for Severe Dyspnea in Terminally Ill Interstitial Pneumonia Patients.
34		Intern Med 2016;55:725-9. doi:10.2169/internalmedicine.55.5362
35	21	Matsuda Y, Maeda I, Tachibana K <i>, et al.</i> Low-Dose Morphine for Dyspnea in
36		Terminally Ill Patients with Idiopathic Interstitial Pneumonias. J Palliat Med 2017.
37		doi:10.1089/jpm.2016.0432
38	22	Kronborg-White S, Andersen CU, Kohberg C, et al. Palliation of chronic
39		breathlessness with morphine in patients with fibrotic interstitial lung disease - a
40		randomised placebo-controlled trial. Respir Res 2020;21:195. doi:10.1186/s12931-
41		020-01452-7
42	23	Ryerson CJ, Collard HR, Pantilat SZ. Management of dyspnea in interstitial lung
43		disease. Curr Opin Support Palliat Care 2010;4:69-75.
44	<u>c</u> (doi:10.1097/SPC.0b013e3283392b51
45	24	Ryerson CJ, Donesky D, Pantilat SZ, et al. Dyspnea in idiopathic pulmonary
46		fibrosis: a systematic review. J Pain Symptom Manage 2012;43:771-82.
47		doi 10.1016/j.jpainsymman.2011.04.026
48	25	Kohberg C, Andersen CU, Bendstrup E. Opioids: an unexplored option for
49		treatment of dyspnea in IPF. <i>Eur Clin Respir J</i> 2016;3:30629.
50	0.0	doi:10.3402/ecrj.v3.30629
51	26	Matsuda Y, Morita T, Miyaji T, <i>et al.</i> Morphine for Refractory Dyspnea in
52		Interstitial Lung Disease: A Phase I Study (JORTC-PAL 05). <i>J Palliat Med</i> 2018.
53	97	doi:10.1089/jpm.2018.0272
54	27	Raghu G, Remy-Jardin M, Myers JL, <i>et al.</i> Diagnosis of Idiopathic Pulmonary Fibrogic An Official ATS/FRS/IRS/ALAT Clinical Practice Guideline Am I Recent
55		Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir
56	90	Crit Care Med 2018;198:e44-e68. doi:10.1164/rccm.201807-1255ST
57	28	Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic
58		Society/European Respiratory Society statement: Update of the international
59		multidisciplinary classification of the idiopathic interstitial pneumonias. Am J
60		

BMJ Open

Respir Crit Care Med 2013;188:733-48. doi:10.1164/rccm.201308-1483ST Bruera E. MacEachern T. Binamonti C. et al. Subcutaneous morphine for d

- 29 Bruera E, MacEachern T, Ripamonti C, *et al.* Subcutaneous morphine for dyspnea in cancer patients. *Ann Intern Med* 1993;119:906-7
- 30 Sessler CN, Gosnell MS, Grap MJ, *et al.* The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. *Am J Respir Crit Care Med* 2002;166:1338-44. doi:10.1164/rccm.2107138
- Unoki K SH, Okimura A, Takeshima C, Aoki K, Otani N, Mochizuki T, Yanagisawa
 Y. Japanese version of the Richmond Agitation Scale. J Jpn Soc Intensive Care Med 2010;17:73-4
- 32 Bestall JC, Paul EA, Garrod R, *et al.* Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. *Thorax* 1999;54:581-6. doi:10.1136/thx.54.7.581
- Yokomichi N, Morita T, Nitto A, et al. Validation of the Japanese Version of the Edmonton Symptom Assessment System-Revised. J Pain Symptom Manage 2015;50:718-23. doi:10.1016/j.jpainsymman.2015.05.014

Authors' Contributions

YM is lead author of the study protocol and principal investigator. YM, TM, SO, KA, TY, and SI participated in the design of the study. SO and TY designed the statistical analysis plan. All authors contributed to writing and revising the manuscript critically, and all gave their final approval of the version to be published.

Funding statement

This work was supported by the following grants: 2018–2020 Grant-in-Aid for Scientific Research (Grant-in-Aid for Young Scientists B; grant number 17K15909) and Osaka Medical Research Foundation for Intractable Diseases (grant number 23-2-41). The funders had no role in the study design and will have no role in the data collection, analysis, or dissemination of study results.

JICN.

Competing interests None declared.

Trial status

The enrolment started in June 2019. At the time of manuscript submission (February 2021), 26 patients have participated. We expect to complete the recruitment by March 2022.

Confidentially

Data will be retained in accordance with the Clinical Trials Act. Participants will be allocated a unique identification (ID) number at enrolment. The master list linking participant personal information and ID number will be maintained in a paper file or password-protected hard drive in a locked room at each institution. Data will be analysed by ID number only. Records will be retained for five years after study completion and then destroyed by the JORTC data centre.

Acknowledgements

This work was supported by the following grants: 2018–2020 Grant-in-Aid for Scientific Research (Grant-in-Aid for Young Scientists B; grant number 17K15909) and Osaka Medical Research Foundation for Intractable Diseases (grant number 23-2-41).

ore terior only

Figure Legend

Figure 1 Flow chart of the study procedures. Participants will be randomised (1:1 allocation ratio) into the morphine group or the placebo group. Assessment will be made at baseline and at 30 minutes, 60 minutes, and 24 hours after treamtment. AEs, Adverse Events; ILD, Interstitial Lung Disease; IPPV, Invasive Positive Pressure Ventilation; NPPV, Non-invasive Positive Pressure Ventilation; RASS, Richmond Agitation Sedation Scale.

toret teries only

BMJ Open




Figure 1 Flow chart of the procedures in the study. Participants will be randomized (1:1 allocation ratio) into the morphine group or the placebo group. Assessment will be made at baseline, 30 minutes, 60 minutes, and 24 hours. AEs, Adverse Events; ILD, Interstitial Lung Disease; IPPV, Invasive Positive Pressure Ventilation; NPPV, Non-invasive Positive Pressure Ventilation; RASS, Richmond Agitation Sedation Scale.

274x383mm (350 x 350 DPI)

Page 27 of 30			BMJ Open	
1 2 3 4 5 6			STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS	
7 8	SPIRIT 2013 Check	klist: Rec	ommended items to address in a clinical trial protocol and related documents*	
9 10 11	Section/item	ltem No	Description Do	Addressed on page number
12 13 14	Administrative inf	ormatior		
15 16	Title	1	Descriptive title identifying the study design, population, interventions, and, if applicated acronym	p1
17 18	Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	р3
19 20		2b	All items from the World Health Organization Trial Registration Data Set	Not applicable
21 22	Protocol version	3	Date and version identifier	р3
23 24	Funding	4	Sources and types of financial, material, and other support	p20
25 26	Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	p1, 20
27 28		5b	Name and contact information for the trial sponsor	Not applicable
29 30 31 32 33 34 35 36 37 38 39 40 41 42		5c	Role of study sponsor and funders, if any, in study design; collection, management, agalysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	p20
		5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	p9
42 43 44 45 46			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	1

			BMJ Open <u>BMJ Open</u>	Page 28 c
1 2	Introduction			
- 3 4 5	Background and rationale	6a	Description of research question and justification for undertaking the trial, including sugmary of relevant studies (published and unpublished) examining benefits and harms for each intervent	p5-6
6 7		6b	Explanation for choice of comparators $\frac{3}{2}$	p12
8 9	Objectives	7	Specific objectives or hypotheses	p6
10 11 12 13	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	p6
14 15	Methods: Participa	nts, inte	erventions, and outcomes	
16 17 18	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	p6-7
19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 5	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	p6-7
	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	p12
		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	Not applicable
		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	Not applicable
		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	p12
	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), methed of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	p13-14
	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	p12-13
			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	2

Page 29 of 30			BMJ Open <u>BMJ Open</u>	
1 2	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was getermined, including clinical and statistical assumptions supporting any sample size calculations	p15
3 4 5	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size $\frac{1}{3}$	p8
6 7	Methods: Assignm	ent of ir	nterventions (for controlled trials) $\overrightarrow{\mathbf{a}}$	
8 9	Allocation:		, May 2	
10 11 12 13 14 15	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	p8
16 17 18 19	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until intervantions are assigned	р8
20 21 22 23	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	p8
23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care provine assessors, data analysts), and how	p9
		17b	If blinded, circumstances under which unblinding is permissible, and procedure for reyealing a participant's allocated intervention during the trial	p9
	Methods: Data collection, management, and analysis			
	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and a description. Reference to where data collection forms can be found, if not in the protocol	p12-13
		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	Not applicable
			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	3

			BMJ Open <u>3</u> . ල	Page 3
1 2 3 4	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	p8-9
5 6 7	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where \vec{g} other details of the statistical analysis plan can be found, if not in the protocol	p14-15
8 9		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	Not applicable
10 11 12 13		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	p15
14 15	Methods: Monitorin	ng	aded d	
16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of way a DMC is not needed	p16
		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	Not applicable
	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	p14
	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process \vec{w} ill be independent from investigators and the sponsor	p10
	Ethics and dissemination			
	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	p15-16
	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility creations, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	p16
43 44 45 46			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	-

Page	Page 31 of 30		BMJ Open <u>B</u> . ව		
1 2	Consent or assent	26a	땡ho will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	p15	
3 4 5 6		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	Not applicable	
7 8 9	Confidentiality	27	How personal information about potential and enrolled participants will be collected, spared, and maintained in order to protect confidentiality before, during, and after the trial	p9-10, 20-21	
10 11 12	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	p20	
13 14 15	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contracted al agreements that limit such access for investigators	Not applicable	
16 17 18	Ancillary and post- trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	p12	
19 20 21 22 23	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healtheare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	p16	
24 25		31b	Authorship eligibility guidelines and any intended use of professional writers	p16	
26 27 28		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	Not applicable	
29 30	Appendices		9, 20		
31 32 33	Informed consent materials	32	Model consent form and other related documentation given to participants and author bed surrogates	Not applicable	
33 34 35 36	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for generic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	Not applicable	
37 38 39 40 41	*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Groug under the Creative Commons				
42 43 44 45			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	ł	